TNON

Tenon Medical Inc

Add to Watchlist

Advanced Chart

1.470

+0.09(6.522%)1D

Overview
Forecast
Valuation
Earnings

Line

Candle

YTD

High

1.490

Open

1.365

VWAP

1.43

Vol

1.13M

Mkt Cap

11.60M

Low

1.3501

Amount

1.62M

EV/EBITDA(TTM)

Total Shares

3.78M

4.33M

EV/OCF(TTM)

P/S(TTM)

0.85

Tenon Medical, Inc. is a medical device company. The Company has developed the Catamaran SI Joint Fusion System that offers a novel, less invasive approach to the SI joint using a single, robust titanium implant. The system features the Catamaran Fixation Device which passes through both the axial and sagittal planes of the ilium and sacrum, stabilizing and transfixing the SI Joint along its longitudinal axis. The angle and trajectory of the Catamaran surgical approach is also designed to provide a pathway away from critical neural and vascular structures and into the strongest cortical bone. Its trademarks include Catamaran, PiSIF, CAT PiSIF, ETAD, CAT SIJ Fusion System, SImmetry, MAINSAIL, SImmetry+, Catamaran Transfixation Fusion Device, Catamaran Transfixation Fusion System, and others. The Catamaran SI Joint Fusion System offers a novel, less invasive Inferior-Posterior approach to the SI joint using a single, robust titanium implant.

Get winning stock picks in minutes

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2025Q3

FY2025Q2

FY2025Q1

1.56M

+102.47%

-0.435

-88.02%

1.27M

+43.4%

-0.470

-53.92%

909.50K

+0.94%

-0.920

-90.8%

Estimates Revision

The market is revising Upward the revenue expectations for Tenon Medical, Inc. (TNON) for FY2025, with the revenue forecasts being adjusted by 10.42% over the past three months. During the same period, the stock price has changed by 18.55%.

Revenue Estimates for FY2025

Revise Upward

+10.42%

In Past 3 Month

EPS Estimates for FY2025

Revise Upward

+0.77%

In Past 3 Month

Stock Price

Go Up

+18.55%

In Past 3 Month

2 Analyst Rating

87.07% Upside

Wall Street analysts forecast TNON stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for TNON is 2.75 USD with a low forecast of 2.50 USD and a high forecast of 3.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

2 Buy

0 Hold

0 Sell

Moderate Buy

87.07% Upside

Current: 1.470

Low

2.50

Averages

2.75

High

3.00

87.07% Upside

Current: 1.470

Low

2.50

Averages

2.75

High

3.00

Alliance Global Partners

Buy

downgrade

2025-05-14

Reason

Alliance Global Partners

Price Target

2025-05-14

downgrade

Buy

Reason

Alliance Global Partners lowered the firm's price target on Tenon Medical to $2.50 from $3 and keeps a Buy rating on the shares, citing lower forecasts after Tenon reported Q1 results that were within the firm's expectations, including a revenue shortfall offset by lower expenses.

Alliance Global Partners

Scott Henry

Strong Buy

Initiates

2025-04-09

Reason

Alliance Global Partners

Scott Henry

Price Target

2025-04-09

Initiates

Strong Buy

Reason

Alliance Global Partners initiated coverage of Tenon Medical with a Buy rating and $3 price target. The company is designing, developing, and selling a surgical implant system to treat severe lower back pain, the analyst tells investors in a research note. The firm expects strong revenue growth for Catamaran and believes it could drive the company into profitability. It believes the market for sacroiliac joint treatment is substantial.

Maxim Group

Anthony Vendetti

Strong Buy

Maintains

$22 → $8

2024-11-15

Reason

Maxim Group

Anthony Vendetti

Price Target

$22 → $8

2024-11-15

Maintains

Strong Buy

Reason

Benchmark

Bruce Jackson

Buy

Reiterates

2024-08-14

Reason

Benchmark

Bruce Jackson

Price Target

2024-08-14

Reiterates

Buy

Reason

See All Ratings

Get winning stock picks in minutes

Valuation Metrics

The current forward P/E ratio for Tenon Medical Inc (TNON.O) is -0.79, compared to its 5-year average forward P/E of -3.26. For a more detailed relative valuation and DCF analysis to assess Tenon Medical Inc 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-3.26

Current PE

-0.79

Overvalued PE

13.40

Undervalued PE

-19.92

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

0.00

Current EV/EBITDA

0.00

Overvalued EV/EBITDA

0.00

Undervalued EV/EBITDA

0.00

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

N/A

5Y Average PS

7.39

Current PS

2.03

Overvalued PS

43.08

Undervalued PS

-28.29